Home > Products > intermedia > Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate
Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate
  • Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoateMethyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate

Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate

Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate
CAS NO:769195-268
Formulae hypotheticae: C₠₠H₉F₃O₃
Aspectus: Pallidus in luce Yellow solidus
Exustio Point: 41 - 43ºC
Molecular pondus:246.18
Usu: Sitagliptin Intermediates​

Mitte Inquisitionem

depictio producti

Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate.CAS NO:769195-268

Usus: Sitagliptin intermedia

Nomen chemicum Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate
Synonyma 2,4,5-Trifluoro-β-oxo-benzenebutanoicum Acidum Methyl Ester
CAS Number 769195-268
Formulae hypotheticae C₠₠H₉F₃O₃
Aspectus Pallida ad lux Yellow solidus
Liquescens punctum 41 - 43ºC
M. Pondus 246.18
Repono leo
Solubilitas DMSO (paulo), Methanol (paulo)
Categoria Aedificium cuneos; Pharmaceutical/API Drug Impurities/Metabolites;
Applications Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate medium syntheticum utile est in synthesi Sitagliptin (S491000); trizolopyrazinum dipeptidylum peptidase (DPP) IV inhibitor ad curationem diabete generis II.

Cautiones pro tutum pertractatio

Pellem et oculos fuge contactum. Fuge formationem pulveris et aerosols. Vitanda patefacio - peculiares instructiones obtine ante use. Provide opportunitatem exhauriendi evacuationem in locis ubi pulvis formatur. For cautiones see section 2.2.

7.2Conditiones repono pro tuto, inter quaslibet incompatibilitates

Copia in loco frigido. Continentiam arcte clausam in loco sicco et bene ventilato.


Hot Tags: Methyl 3-Oxo-4-(2,4,5-trifluorophenyl) butanoate, China, Suppliers, Manufacturers, Factory

Product Tag

Related Categoria

Mitte Inquisitionem

Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept